Resverlogix Corp. (TSE:RVX) Senior Officer Dr. Jan Ove Johansson sold 10,000 shares of the company’s stock in a transaction dated Tuesday, July 9th. The stock was sold at an average price of C$3.00, for a total value of C$29,979.84. Following the transaction, the insider now directly owns 144,160 shares of the company’s stock, valued at C$432,189.37.
RVX stock opened at C$2.74 on Friday. The firm has a market capitalization of $559.38 million and a PE ratio of -4.54. The stock’s 50-day moving average price is C$3.08. Resverlogix Corp. has a fifty-two week low of C$2.25 and a fifty-two week high of C$4.94.
Separately, Roth Capital reaffirmed a “buy” rating on shares of Resverlogix in a research report on Thursday, May 23rd.
Resverlogix Corp., a development stage company, develops small molecule therapeutics for bromodomain and extra-terminal (BET) inhibitior in the United States and Canada. It is developing apabetalone (RVX-208), a small molecule selective BET bromodomain inhibitor that is in Phase III clinical trials for the treatment of patients with cardiovascular diseases, diabetes mellitus, chronic kidney diseases, renal diseases, peripheral artery diseases, orphan diseases, and neurodegenerative diseases.
Receive News & Ratings for Resverlogix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Resverlogix and related companies with MarketBeat.com's FREE daily email newsletter.